{"id":509039,"date":"2021-07-01T16:04:06","date_gmt":"2021-07-01T20:04:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/"},"modified":"2021-07-01T16:04:06","modified_gmt":"2021-07-01T20:04:06","slug":"cidara-therapeutics-provides-leadership-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/","title":{"rendered":"Cidara Therapeutics Provides Leadership Update"},"content":{"rendered":"
\n

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO.<\/p>\n

\u201cOn behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and Janssen Pharmaceuticals,\u201d said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. \u201cHe has helped build an outstanding finance team and supported the strengthening of our balance sheet, which has enabled us to efficiently advance our rezafungin Phase 3 programs and expand our Cloudbreak immunotherapy antiviral platform. We wish Jamie the best in his future endeavors.\u201d<\/p>\n

Concurrent with Mr. Levine\u2019s resignation, Dr. Stein will assume the role of Cidara\u2019s principal financial officer, and Brady Johnson has been promoted to vice president, finance, and will assume the role of the Company\u2019s principal accounting officer.<\/p>\n

\n About Cidara Therapeutics<\/strong>
\n
Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company\u2019s portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to AVCs for the prevention and treatment of influenza and other viral diseases from Cidara\u2019s proprietary Cloudbreak\u00ae<\/sup> antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com<\/a>.<\/p>\n

\n INVESTOR CONTACT:<\/strong>
\n
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com<\/p>\n

\n MEDIA CONTACT:<\/strong>
\n
Patrick Bursey
LifeSci Communications
(203) 430-9545
pbursey@lifescicomms.com<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO. \u201cOn behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and Janssen Pharmaceuticals,\u201d said Jeffrey Stein, Ph.D., … <\/p>\n

Continue reading “Cidara Therapeutics Provides Leadership Update”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-509039","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nCidara Therapeutics Provides Leadership Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cidara Therapeutics Provides Leadership Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO. \u201cOn behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and Janssen Pharmaceuticals,\u201d said Jeffrey Stein, Ph.D., … Continue reading "Cidara Therapeutics Provides Leadership Update"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-07-01T20:04:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cidara Therapeutics Provides Leadership Update\",\"datePublished\":\"2021-07-01T20:04:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/\",\"name\":\"Cidara Therapeutics Provides Leadership Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=\",\"datePublished\":\"2021-07-01T20:04:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cidara-therapeutics-provides-leadership-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cidara Therapeutics Provides Leadership Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cidara Therapeutics Provides Leadership Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/","og_locale":"en_US","og_type":"article","og_title":"Cidara Therapeutics Provides Leadership Update - Market Newsdesk","og_description":"SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will provide transitional support to a successor CFO. \u201cOn behalf of the entire Cidara team and board of directors, I want to thank Jamie for his financial leadership, including his significant contributions to our collaborations with Mundipharma and Janssen Pharmaceuticals,\u201d said Jeffrey Stein, Ph.D., … Continue reading \"Cidara Therapeutics Provides Leadership Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/","og_site_name":"Market Newsdesk","article_published_time":"2021-07-01T20:04:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cidara Therapeutics Provides Leadership Update","datePublished":"2021-07-01T20:04:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/","name":"Cidara Therapeutics Provides Leadership Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=","datePublished":"2021-07-01T20:04:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3NDE5NiM0Mjc5Njk2IzIwMTczOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cidara-therapeutics-provides-leadership-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cidara Therapeutics Provides Leadership Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509039","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=509039"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/509039\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=509039"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=509039"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=509039"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}